Literature DB >> 6653035

Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.

L A Bauer, R A Blouin.   

Abstract

The Michaelis-Menten pharmacokinetic parameters Vmax and Km were calculated for 135 epileptic paediatric patients receiving phenytoin as their only anticonvulsant therapy. Mean Vmax and Km values were 13.95 mg/kg/day and 6.59 micrograms/ml for 0.5 to 3-year-old patients, 10.93 mg/kg/day and 6.82 micrograms/ml for the 4 to 6 year age group, 10.05 mg/kg/day and 6.51 micrograms/ml for the 7 to 9-year-olds, and 8.25 mg/kg/day and 5.69 micrograms/ml for the 10 to 16 year group. Using analysis of variance, the Vmax values were significantly different (p less than 0.01) but the Km values were not. Linear regression analysis of Vmax versus age revealed a significant decline in Vmax with age (r = -0.554; p less than 0.001). A plot of Km versus age showed a poor correlation (r = -0.170) and a large amount of variability. Based on this data, the youngest age group would require on average 62% more phenytoin/kg/day than the oldest age group in order to maintain a steady-state phenytoin concentration of 15 micrograms/ml. Because of these age-related pharmacokinetic differences, phenytoin dosages may require adjustment as paediatric patients become older.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653035     DOI: 10.2165/00003088-198308060-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  15 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

2.  Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children.

Authors:  L G Borofsky; S Louis; H Kutt; M Roginsky
Journal:  J Pediatr       Date:  1972-11       Impact factor: 4.406

3.  Predicting phenytoin dose - a revised nomogram.

Authors:  B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

4.  Inter-ethnic and inter-phenotype differences among Ghanaians and Caucasians in the metabolic hydroxylation of phenytoin [proceedings].

Authors:  B Andoh; J R Idle; T P Sloan; R L Smith; N Woolhouse
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

5.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

6.  The elimination of phenytoin in man.

Authors:  M J Eadie; J H Tyrer; F Bochner; W D Hooper
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 May-Jun       Impact factor: 2.557

7.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

8.  Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.

Authors:  K Chiba; T Ishizaki; H Miura; K Minagawa
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

9.  Differences in single dose phenytoin kinetics between Greenland Eskimos and Danes.

Authors:  N Kromann; J Christiansen; H Flachs; M Dam; E F Hvidberg
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  8 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Bayesian forecasting in paediatric populations.

Authors:  M M Fernández de Gatta; M J García; J M Lanao; A Domínguez-Gil
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

5.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.

Authors:  Philip E Empey; Nieves Velez de Mendizabal; Michael J Bell; Robert R Bies; Kacey B Anderson; Patrick M Kochanek; P David Adelson; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.